A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
← catalyst calendarNCT07220616 · readout in 1,564 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
420estimated
Sites
6
Countries
France, Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-16 | actual | When the study began enrolling |
| Primary completion | 2030-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hematological Malignancies
- B-cell Non-Hodgkin Lymphoma
Interventions
- Drug: DS3790a
- Drug: Combination drug
- Drug: Combination drug
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Reporting Dose-limiting Toxicities, Treatment-emergent Adverse Events, Serious Adverse Events, Adverse Events of Special Interest, and Deaths in Participants With Hematological Malignancies
measured Baseline up to 5 years
Complete Response in Participants With Hematological Malignancies by Blinded Independent Central Review (Cohort A Randomization Optimization Phase, Cohort A Phase 2)
measured Baseline up to 5 years
Complete Response in Participants With Hematological Malignancies by Investigator Assessment (Cohort B Randomization Optimization Phase)
measured Baseline up to 5 years
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed